<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432884</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111-106</org_study_id>
    <nct_id>NCT03432884</nct_id>
  </id_info>
  <brief_title>A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects</brief_title>
  <official_title>A Two-Part Study Consisting of a Randomized, Placebo-Controlled, Single Dose Safety and Tolerability Study (Part A) Evaluating a Supratherapeutic Dose of Zanubrutinib Followed by a Randomized, Placebo- and Positive-Controlled, Crossover Study (Part B) to Evaluate the Effect of Zanubrutinib on Cardiac Repolarization in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Two-Part Phase 1 Study to Investigate A) Safety and Tolerability of Supratherapeutic dose
      of Zanubrutinib (BGB-3111) and B) Effect of Zanubrutinib on Cardiac Repolarization in Healthy
      Subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Two-Part Phase 1 Study.

      Part A: This is a randomized, placebo-controlled, double blind, single dose study to evaluate
      the safety and tolerability of a single oral supratherapeutic dose of zanubrutinib in eight
      (8) subjects.

      Part B: This is a randomized, placebo and positive-controlled, double-blind, 4-way crossover
      study being conducted in about 28 subjects to investigate the effect of a single therapeutic
      dose of zanubrutinib, a supratherapeutic dose of zanubrutinib and placebo on cardiac
      repolarization. Open-label Moxifloxacin (400 mg), a fluoroquinolone broad spectrum antibiotic
      will be used as a positive control.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Actual">April 16, 2018</completion_date>
  <primary_completion_date type="Actual">April 16, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Part A: Single Group Part B: Crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Part A: zanubrutinib and placebo will be double-blind Part B: zanubrutinib and placebo will be double-blind; Moxifloxacin will be open-label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Incidence of treatment-emergent adverse events (safety and tolerability)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Incidence of treatment-emergent adverse events reported for zanubrutinib compared with placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Corrected QT interval [QTc]</measure>
    <time_frame>Up to 2 days</time_frame>
    <description>Evaluate the effects of single doses of zanubrutinib on the corrected QT interval [QTc] using the Fridericia correction [QTcF]) compared with placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: PK Parameters</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>Plasma concentrations of zanubrutinib to evaluate protocol specified PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Heart Rate (HR)</measure>
    <time_frame>Up to 2 days</time_frame>
    <description>Evaluate the effects of a single dose of zanubrutinib and a single supratherapeutic dose of zanubrutinib on heart rate (HR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: PR Intervals</measure>
    <time_frame>Up to 2 days</time_frame>
    <description>Evaluate the effects of a single dose of zanubrutinib and a single supratherapeutic dose of zanubrutinib on PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: QRS Intervals</measure>
    <time_frame>Up to 2 days</time_frame>
    <description>Evaluate the effects of a single dose of zanubrutinib and a single supratherapeutic dose of zanubrutinib on QRS Intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: PK Parameters</measure>
    <time_frame>Up to 2 days</time_frame>
    <description>Plasma concentrations of zanubrutinib to evaluate protocol specified PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Incidence of treatment-emergent adverse events (safety and tolerability)</measure>
    <time_frame>Up to 16 days</time_frame>
    <description>Incidence of treatment-emergent adverse events reported for zanubrutinib</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part A: BGB-3111</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: BGB-3111, Placebo, and Moxifloxicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-3111</intervention_name>
    <description>Subjects will receive BGB-3111</description>
    <arm_group_label>Part A: BGB-3111</arm_group_label>
    <arm_group_label>Part B: BGB-3111, Placebo, and Moxifloxicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive Placebo</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_label>Part B: BGB-3111, Placebo, and Moxifloxicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Subjects will receive Moxifloxicin</description>
    <arm_group_label>Part B: BGB-3111, Placebo, and Moxifloxicin</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: All subjects

          1. Body mass index (BMI) 18 - 33 kg/m2, inclusive.

          2. In good general health as assessed by the Investigator.

          3. Females of non-child bearing potential.

          4. Males without a vasectomy will agree to use required barrier contraception, and will
             agree to not donate sperm from the time of the first dose of BGB-3111 until â‰¥ 90 days
             after the last dose of BGB-3111.

          5. Able to comprehend and willing to sign consent.

        Exclusion Criteria: All subjects

          1. Subjects with a clinically relevant history or presence of any clinically significant
             disease.

          2. Personal or known family history of congenital or acquired long QT syndrome or
             cardiovascular disease.

          3. Women of child-bearing potential.

          4. History of alcoholism or drug/chemical abuse within 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Frontage Clinical Services, Inc.</name>
      <address>
        <city>Secaucus</city>
        <state>New Jersey</state>
        <zip>07094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

